AACR 2025 | KEYLYNK-007: olaparib and pembrolizumab in HRRm cancers
Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase II KEYLYNK-007 trial (NCT04123366) of olaparib and pembrolizumab in patients with advanced solid tumors harboring homologous recombination repair mutations (HRRm) or deficiencies. The combination demonstrated encouraging antitumor activity, especially in BRCA-mutated tumors, with responses observed across a wide range of cancer types. Treatment was generally well tolerated. Ongoing biomarker analyses aim to further clarify predictors of response in this tumor-agnostic approach. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
